Fundacion Grupo Espanol De Investigacion En Cancer De Mama

7 trials Academic / non-commercial

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

0 Recruiting

6 Completed trials

5 Countries active

20 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 2 Phase II: 3 Phase I/II: 1 Phase IV: 1

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

HER2 positive breast cancer 2 Hormone receptor positive breast cancer 1 Hormone receptor negative HER2 positive breast cancer 1

Top IMPs

ABEMACICLIB 2 ANASTROZOLE 1 EXEMESTANE 1 FULVESTRANT 1 GOSERELIN 1 LETROZOLE 1 LEUPRORELIN ACETATE 1 LOPERAMIDE HYDROCHLORIDE 1 RIBOCICLIB 1 TUCATINIB 1

All trials

7 total

Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6… Pending

2025-522848-40-00 Phase IV 1 country ABEMACICLIB; ANASTROZOLE; EXEMESTANE; GOSERELIN; LETROZOLE; LEUPRORELIN ACETATE;…
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 Phase II 4 countries LOPERAMIDE HYDROCHLORIDE
Clinical trial to compare efficacy and safety of standard chemotherapy versus letrozole plus abemaciclib, chosen randomly, as neoadjuvant th… Ended

2024-514395-40-00 Phase II 1 country ABEMACICLIB
"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended

2024-515368-29-00 Phase III 1 country
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Phase I/II 1 country TUCATINIB
A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr… Ended

2024-514611-98-00 Phase III 1 country
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg… Ended

2024-516132-10-00 Phase II 2 countries FULVESTRANT

Showing 1–7 of 7 trials

← All sponsors A–Z